PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete If Known	
Application Number	09/901,910-Conf. #7856
Filing Date	July 11, 2001
First Named Inventor	Haodong Li
Art Unit	1635
Examiner Name	T. C. Gibbs
Attorney Docket Number	PF126P2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	AK	XIE et al., "CYR61, an angiogenic inducer, is over-expressed and estrogen inducible in breast cancer." Proceedings of 91st Annual Meeting for Amer. Assoc. for Cancer Res., Vol. 41 (April 1, 2000)	
	AL	BABIC et al., "Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo." Mol Cell Biol. 1999 Apr;19(4):2958-66.	
	AM	JEDSADAYANMATA et al., "Activation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin alpha(IIb)beta(3)." J Biol Chem. 1999 Aug 20;274(34):24321-7.	
	AN	SHIMO et al., "Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells." J. Biochemistry v. 124(1) p. 130-140 (July 1998).	
~~——~~	~~AO~~	~~Supplemental European Search Report for EP. App. No. EP 01 95 4638 (December 2, 2004).~~	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	5/26/05